{"id":"NCT02851797","sponsor":"Italfarmaco","briefTitle":"Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy","officialTitle":"Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-06","primaryCompletion":"2022-02-22","completion":"2022-02-22","firstPosted":"2016-08-02","resultsPosted":"2023-02-02","lastUpdate":"2023-02-02"},"enrollment":179,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Duchenne Muscular Dystrophy"],"interventions":[{"type":"DRUG","name":"givinostat","otherNames":["ITF2357"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"givinostat","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective\n\nThe primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.\n\nSecondary Objectives\n\nThe secondary objectives of this study were:\n\n* To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects\n* To evaluate the PK profile of givinostat administered chronically in DMD subjects\n* To evaluate the impact on quality of life (QoL) and activities of daily living of givinostat versus placebo administered chronically.","primaryOutcome":{"measure":"Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment","timeFrame":"Baseline and 18 months","effectByArm":[{"arm":"Givinostat","deltaMin":1.27,"sd":0.04},{"arm":"Placebo","deltaMin":1.48,"sd":0.058}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0345"}]},"eligibility":{"minAge":"6 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":42,"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Serbia","Spain","United Kingdom"]},"refs":{"pmids":["38508835"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":118},"commonTop":["Platelet count decreased","Diarrhoea","Nasopharyngitis","Vomiting","Headache"]}}